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Case Report
Introduction
Interferon-γ receptor 1 (IFNGR1) deficiency is a rare 
immune deficiency characterized by selective susceptibility 
to mycobacterial disease caused by genetic mutations in the 
IFNGR1 gene.1 It comprises about 8% of patients in a group 
of diseases referred collectively as to Mendelian susceptibil-
ity to mycobacterial disease (MSMD) syndromes.2 Patients 
with MSMD feature genetic defects in genes encoding com-
ponents of the interleukin (IL)-12/23-IFN-γ (interferon-γ) 
axis, a critical mechanism in the clearance of intracellular 
infections.3
The IFNGR1 gene maps to the chromosome 6q23.3. It is 
composed of 22 868 base pairs arranged in 7 exons.4 On IFN-
γ binding, IFNGR1 chain induces the assembly of the IFN-γ 
receptor (an IFNGR1 and IFNGR2 heterodimer) with subse-
quent activation of constitutively associated Janus kinases 1 
and 2 (Jak1/2) and the downstream signal transducer and 
activator of transcription 1 (STAT 1) mediated gene tran-
scription.5 In the normal host, mycobacteria typically induce 
IL-12 production by macrophages, which, in turn, trigger 
IFN-γ production. In patients with IFNGR1 deficiency, mac-
rophages fail to activate on IFN-γ stimulation from T- and 
NK-cells, rendering the host susceptible to mycobacteria and 
intramacrophagic microorganisms.2,5
Clinically, the characterization of IFNGR1 deficiency–
associated mutations translates in important differences in 
disease severity and treatment approach. Complete autoso-
mal recessive IFNGR1 deficiency is characterized by early 
onset of disseminated life-threatening infections by low-
virulent mycobacteria, lack of response to IFN-γ cytokine 
replacement therapy, and high mortality.6,7 To date hemato-
poietic stem cell transplant is the only curative therapy 
available for these patients.6 Conversely, the clinical pheno-
type of the autosomal recessive partial and autosomal domi-
nant forms is milder, usually with later onset, less severe 
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Abstract
Mendelian susceptibility to mycobacterial diseases (MSMD) are a spectrum of inherited disorders characterized by localized or 
disseminated infections caused by atypical mycobacteria. Interferon-γ receptor 1 (IFNGR1) deficiency was the first identified 
genetic disorder recognized as MSMD. Mutations in the genes encoding IFNGR1 can be recessive or dominant and cause 
complete or partial receptor deficiency. We present the case of a 2½-year-old boy with a history of recurrent wheezing, 
diagnosed with endobronchial mycobacterial infection. Immunological workup revealed a homozygous nonsense mutation in 
the IFNGR1 gene, a novel mutation predicted in silico to cause complete IFNGR1 deficiency. This case demonstrates that (a) 
Interferon-γ receptor deficiency can present resembling common disorders of the lung; (b) mycobacterial infections should 
be suspected when parenchymal lung disease, hilar lymphadenopathy, and endobronchial disease are present; and (c) high 
index of suspicion for immunodeficiency should be maintained in patients with disseminated nontubercular mycobacterial 
infection.
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infections, favorable response to IFN-γ and antibiotic ther-
apy, and better survival rates without hematopoietic stem 
cell transplant.7,8
In this article, we describe the case of a toddler boy with 
a history of recurrent wheezing found to have an invasive 
endobronchial mycobacterial infection. Genetic testing dem-
onstrated a homozygous c.672 A>G nonsense mutation in 
exon 5 of the IFNGR1 gene, a novel mutation predicted to 
cause a stop codon and complete IFNGR1 deficiency. The 
variant c.672G>A, detected in this patient, is novel and has 
not been previously described in the literature. This case also 
illustrates that IFNGR1 deficiency can present with common 
respiratory symptoms and endobronchial disease in early 
childhood.
Case Report
A 2½-year-old boy was admitted with a history of approxi-
mately 1 month of recurring fever, productive cough, and 
intermittent episodes of wheezing and dyspnea. He had been 
previously treated with azithromycin and cefdinir with only 
partial improvement. His history was remarkable for recur-
rent episodes of wheezing and cough approximately every 4 
to 6 weeks since the age of 15 months. He had been treated 
with short courses of oral steroids and antibiotics intermit-
tently with improvement. Otherwise he was a healthy well-
developed boy. He was born at full term after an uneventful 
pregnancy. His family history was unremarkable and there 
was no history of consanguinity.
At the time of presentation, he was tachypneic and tachy-
cardic with a normal pulsoximetry on exam. His chest exam 
revealed bilateral wheezing. His abdomen was soft and non-
distended with no visceromegaly. He had no clubbing. His 
physical exam was otherwise unremarkable. Laboratory 
analysis revealed mild anemia with a hemoglobin of 8.8 g/dL 
(age-matched control range 11.5-13.5 g/dL). He had a white 
cell count of 14.73 K/uL with normal absolute neutrophil and 
lymphocyte counts (Table 1). Basic metabolic panel and 
liver function tests were within normal limits.
Chest-X-ray revealed mediastinal widening (Figure 1A). 
A computed tomography scan of the chest showed extensive 
mediastinal lymphadenopathy with compression of the right 
Table 1. Summary of Laboratory Findingsa.
Test Patient’s Results Age-Matched Control Range
White cell count 14.73 K/uL 5.5-17 K/uL
Hemoglobin 8.8 g/dL 11.5-13.5 g/dL
Platelets 282 K/uL 172-440 K/uL
Neutrophil count 11.04 K/uL 1.5-8.5 K/uL
Lymphocyte count 2.81 K/uL 2.0-9.5 K/uL
CD3 T cells 61% 56% to 75%
CD3+ CD4+ T cells 31% 28% to 47%
CD3+ CD8+ T cells 20% 16% to 30%
Maximum proliferation of PHA as % CD45 58.9% ≥49.9%
Maximum proliferation of PHA as % CD3 64.3% ≥58.5%
aPatient had mild chronic anemia with otherwise normal T and B blood cell counts and lymphocyte subpopulations. Lymphocyte proliferation to phytohe-
magluttinin (PHA) yielded normal values. Dihydrorhodamine test for chronic granulomatous disease showed normal oxidative burst.
Figure 1. Radiographic and bronchoscopic findings. (A) Mediastinal widening on initial chest radiograph. (B) Extensive mediastinal 
lymphadenopathy, right main bronchus compression with right upper lobe collapse on chest computed tomography scan during hospital 
admission. (C) Endobronchial masses found during bronchoscopy. Mycobacterium avium-intracellulare complex was isolated from 
endobronchial granulation tissue.
 at GEORGE WASHINGTON UNIVERSITY on November 15, 2016hic.sagepub.comDownloaded from 
Gutierrez et al 3
bronchus and collapse of the right upper lobe (Figure 1B). A 
bronchoscopy revealed cauliflower-like endobronchial 
masses with one occluding the right main bronchus (Figure 
1C). Despite antibiotic therapy, the patient remained febrile 
and with active respiratory symptoms. Because of a high sus-
picion of possible mycobacterial infection, empiric therapy 
was initiated. Mycobacterium avium-intracellulare complex 
was isolated from endobronchial granulation tissue, and 
bronchoalveolar lavage fluid. After initiation of anti-myco-
bacterial therapy the patient improved clinically. He was dis-
charged from the hospital on therapy with isoniazid, 
ethambutol, azithromycin, and rifampicin. He remained afe-
brile and right upper lobe atelectasis had resolved at follow-
up after 4 weeks of therapy.
An invasive infection by Mycobacterium avium-intracel-
lulare complex raised the concern for an underlying immune 
defect. Initial immunologic evaluation showed normal T, B, 
and NK lymphocyte counts with CD4+ CD8+ subpopula-
tions within the normal age-range. Dihydrorhodamine test 
for chronic granulomatous disease showed normal oxidative 
burst. Lymphocyte proliferation was preserved in response to 
mitogen phytohemagluttinin. Genetic analysis demonstrated 
a nonsense homozygous c.672G>A mutation in the IFNGR1 
gene (Figure 2A). We used publicly available software to 
simulate the potential deleterious effect of the found muta-
tion.9,10 Our in silico modeling predicted the c.672G>A sub-
stitution to produce a stop codon at the end of exon 5 causing 
an amino acid change (p.Trp224X) and truncation in the 
extracellular domain of IFNGR1 likely to produce complete 
deficiency (Figure 2B). Additional functional studies were 
unavailable to us as patient transferred to another institution 
for further care.
Discussion
We report a case of a 2½-year-old boy presenting with recur-
rent asthma-like symptoms and a mediastinal mass. Bilateral 
endobronchial lesions and extensive lymphadenopathy sec-
ondary to an atypical mycobacterial infection were found. 
Subsequently, an underlying primary immunodeficiency 
associated with a novel nonsense homozygous mutation in 
the IFNGR1 gene was characterized.
IFNGR1 deficiency can be inherited as an autosomal 
recessive or an autosomal dominant trait. Functionally, the 
defect may be partial or complete based on whether the 
defective receptor is expressed on the cell surface and can 
Figure 2. (A) Sequence analysis identified a nonsense homozygous c.672G>A mutation in the IFNGR1 gene. This mutation is predicted 
to produce a stop codon (TGA) with the resulting protein truncation. (B) Wild type DNA and protein sequences. In the normal protein, 
the codon TGG encodes for a Tryptophan residue (W) at position 224 (p.Trp224x).
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bind IFN-γ.2,5,8 The autosomal recessive complete deficiency 
is the rarest but most severe disease form. Approximately 32 
individuals carrying 25 mutations have been diagnosed with 
this variant worldwide.2 Most identified mutations to date 
involve the extracellular domain of the receptor (exons 1 to 
5), which usually results in complete absence of protein 
expression.1,6,7 In contrast, mutations associated with autoso-
mal dominant IFNGR1 deficiency have been found in parts 
of the gene encoding for the intracellular segment of the 
receptor (last part of exon 6 and exon 7).1,7 These mutations 
produce defective intracellular signaling and receptor recy-
cling but allow the expression of a partially functioning 
receptor on the cell surface.5,8 These differences translate in 
a milder clinical course, later onset, and response to IFN-γ 
replacement, which along with antibiotic prophylaxis are the 
first line of therapy.6-8
We describe a novel nonsense mutation in the IFNGR1 gene 
that has not been previously described in association with a spe-
cific disease phenotype. Our in silico model predicted the 
c.672G>A mutation present in this patient to produce a stop 
codon at the end of exon 5 with the corresponding amino acid 
change (p.Trp224X; Figure 2B). This mutation is located in the 
area of the IFNGR1 gene encoding for the receptor’s extracellu-
lar domain, predicted to result in a truncated protein and in likely 
complete IFNGR1 deficiency (Figure 2B and Figure 3). Of note, 
in silico analyses, although informative in experimental settings, 
should not replace appropriate testing for clinical purposes. In 
this specific case, additional functional studies are needed to con-
firm the diagnosis of complete IFNGR1 deficiency. IFNGR1 
staining by flow cytometry yields information on whether the 
receptor is expressed on the cell surface.8 Additional suitable 
options to evaluate IFNGR1 function include immunoblotting or 
Figure 3. In silico modeling and alignment of the wild type and mutated IFNGR1 extracellular domain. The red segment represents the 
aligned 223 residues before the protein truncation. The purple segment corresponds to the unaligned residues of the wild protein after 
the truncation at position 224. (Cn3D viewer—National Center for Biotechnology Information, The National Library of Medicine.)
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flow cytometric evaluation of STAT1 phosphorylation after IFN-
α and IFN-γ stimulation.8 Establishing the residual protein func-
tion (partial vs absent) is essential in determining additional 
therapeutic choices and long-term outcome.
In summary, this case highlights the need of excluding pri-
mary immune defects in patients presenting with low-virulent 
nontubercular mycobacterial infections. In our case, a plain 
chest radiograph provided the initial diagnostic clue to an atypi-
cal cause, underscoring the importance of baseline chest X-ray 
evaluation of the wheezing child. This case reminds us that 
causes of intrinsic and extrinsic airway compression should be 
kept in the differential diagnosis when evaluating patients with 
asthma-like symptoms. Although monogenic primary immuno-
deficiencies are rare, they should be fully explored once the ini-
tial clinical suspicion arises. Early diagnosis not only affects 
patients’ prognosis but also proves definitive for other family 
members who may need genetic counseling. Finally, given that 
patients with complete and partial IFNGR1 deficiency require 
radically different therapy, determining the functional effect of 
genotyping findings in IFNGR1 deficiency cases is crucial and 
can provide novel insights into the complex genetic mecha-
nisms implicated in the control of IFN-γ receptor function.
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